<DOC>
	<DOC>NCT01475383</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of an investigational compound designated PF-03654746 compared to placebo in the treatment of adults with Tourette's Syndrome. The study will also explore the pharmacokinetics of PF-03654746 in adults with Tourette's Syndrome.</brief_summary>
	<brief_title>Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome</brief_title>
	<detailed_description>The study was terminated 11-Apr-2012 due to an internal reassessment of priorities by the sponsor. The decision to terminate was not based on any safety or efficacy concerns.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<criteria>Primary diagnosis of Tourette's Syndrome in Englishspeaking male or female adults 18 to 55 years of age who are in generally good health. Free of medications to treat tics for at least 6 weeks prior to randomization. Females of childbearing potential must use medically acceptable birth control for the duration of the study and for 28 days after study participation. Tic treatment including protocolspecified drugs, training in ticsuppressing behavioral techniques, habit reversal training or use of Onabotulinum toxin A injection. History or neurologic evidence of a secondary tic disorder, psychosis, bipolar disorder, tardive dyskinesia, untreated or unstable DSMIV Axis I disorder requiring treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Tourette's Syndrome in adults</keyword>
	<keyword>Safety and Efficacy</keyword>
	<keyword>Randomized</keyword>
	<keyword>Placebo Control</keyword>
	<keyword>Cross-over</keyword>
</DOC>